- In late February 2026, Phathom Pharmaceuticals reported fourth-quarter and full-year 2025 results revealing a much tinyer net loss of US$21.15 million for the quarter and US$221.25 million for the year, alongside guidance for 2026 that includes expected operating profitability (excluding stock-based compensation) launchning in the third quarter.
- The company also strengthened its financial position through a US$130 million equity raise, reworked term loans, and ongoing uptake of its VOQUEZNA gastrointestinal treatment, which toreceiveher appear to underpin its plan to reach operating profitability in 2026 and improve cash flow thereafter.
- We’ll now examine how Phathom’s path toward operating profitability in 2026 may reshape its pre-existing investment narrative for investors.
This technology could replace computers: discover 22 stocks that are working to build quantum computing a reality.
Phathom Pharmaceuticals Investment Narrative Recap
To own Phathom today, you required to believe VOQUEZNA can support a focutilized GI franchise that scales to profitability while reimbursement and competition remain manageable. The latest results, narrower losses, and 2026 guidance toward operating profitability reinforce the near term catalyst around VOQUEZNA prescription and revenue traction, but they do not reshift the core risk of single product depfinishence and exposure to U.S. payer behavior.
The most relevant recent announcement is Phathom’s 2026 guidance calling for net revenues of US$320 million to US$345 million and operating profitability (excluding stock based compensation) starting in the third quarter. For many investors, this guidance frames how quickly VOQUEZNA uptake, cost discipline, and the strengthened balance sheet from the US$130 million equity raise could translate into a self funding business, ahead of any contribution from pipeline programs like the EoE Phase II trial.
Yet while this profitability path is encouraging, investors should still recognize the risk that VOQUEZNA’s U.S. reimbursement and pricing environment could…
Read the full narrative on Phathom Pharmaceuticals (it’s free!)
Phathom Pharmaceuticals’ narrative projects $612.6 million revenue and $155.5 million earnings by 2028.
Uncover how Phathom Pharmaceuticals’ forecasts yield a $22.90 fair value, a 82% upside to its current price.
Exploring Other Perspectives
The lowest analysts sounded far more cautious, assuming revenue around US$470.2 million by 2028 and no profitability by then, which contrasts sharply with today’s profitability focutilized guidance.
Explore 3 other fair value estimates on Phathom Pharmaceuticals – why the stock might be worth less than half the current price!
Reach Your Own Conclusion
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Ready For A Different Approach?
Our top stock finds are flying under the radar-for now. Get in early:
This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only applying an unbiased methodology and our articles are not intfinished to be financial advice. It does not constitute a recommfinishation to purchase or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focutilized analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.
New: Manage All Your Stock Portfolios in One Place
We’ve created the ultimate portfolio companion for stock investors, and it’s free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Leave a Reply